Jürgen K.
- Country
- Germany
- Department
- 127603: Hematology/Oncology
Research Overview
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- Phase 3 Multicenter Open-label Randomized Study of Gilteritinib, Gilteritinib Plus Azacitidine, and Azacitidine in Newly Diagnosed FLT3-Mutated AML
- Phase III Randomized Trial of Decitabine, Venetoclax, and Tretinoin in Acute Myeloid Leukemia Patients Ineligible for Induction Chemotherapy
Data & Insights
Has run more than one trial at 144 of 318 partner sites.
Specializations
Primary Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML), with particular focus on both newly diagnosed cases and those with refractory or relapsed disease states. Their research encompasses diverse genetic profiles including FLT3-ITD negative AML and cases with intermediate or adverse-risk genetics.
- Newly diagnosed AML treatment approaches
- Refractory and relapsed AML management
- Genetic-based therapeutic strategies
Myeloid Disorders
Their expertise extends to various myeloid conditions, including myelodysplastic syndrome (MDS) and its subtypes, particularly MDS with excess blasts-2. The investigator also focuses on chronic myelomonocytic leukemia (CMML) and AML with myelodysplasia-related changes.
- MDS treatment strategies
- CMML therapeutic approaches
- Complex myeloid conditions
Therapeutic Innovation
The investigator explores novel therapeutic agents including venetoclax, tuspetinib, and L-Annamycin in combination with established treatments. Their work involves both induction and consolidation therapy approaches, focusing on improving survival outcomes in various hematologic conditions.
- Novel drug combinations
- Innovative treatment protocols
- Long-term therapeutic strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.